Patients Alpha 1
"We take care of our patients"
Our essential objective is to provide personalized, high-quality healthcare to our patients.
We are a team of pulmonologists specialized in COPD and experienced in AATD.
In addition, the functional testing laboratory is also located on the same floor, facilitating interaction with the complete functional assessment.
ASSISTANCE AND TREATMENT OF OUR PATIENTS
"Personalized attention"
Knowledge about Alpha-1 Antitrypsin Deficiency is constantly evolving.
Continuous development of skills and attitudes aimed at meeting the patient’s needs and expectations is essential.
Our center has a consulting room that covers the San Cecilio Clinical Hospital (HU) Health Area.
We also maintain relationships with pulmonology professionals from hospitals in Granada and the surrounding province for specific consultations.
The Granada Alfa 1 Center of Excellence is located on the 4th floor (4C01) of the consulting room at San Cecilio Clinic Hospital.
Alpha 1 Patient Association
We ensure healthcare that guarantees cures through programs and interest groups.
Patient associations are essential for defending the interests of those affected by Alpha-1 Antitrypsin Deficiency and their families.
At the Andalusian Alfa 1 Center in Granada, we have established contacts with patients with AATD; we also participate in joint activities with them to provide support and address their concerns.
Alfa 1 Spain Association
The Alfa-1 Association of Spain is an organization that was formed in 1999 by a group of patients with the aim of defending their interests as those affected by Alpha-1 Antitrypsin Deficiency.
Misison
One of our goals as an organization is to defend social and healthcare services to ensure access to care and treatment for patients with this lung disease.
Furthermore, this organization seeks to promote values of coexistence, mutual support, and strengthening social and personal ties.
In addition, we disseminate information about this disease and its status as a rare disease to raise positive social awareness.
In general, we support affected patients and their families, especially those recently diagnosed.
Finally, we promote early detection of this genetic condition to improve the prevention and prognosis of illnesses associated with the Deficiency.
Through this partnership, we aim to ensure patients have access to the best care, including intravenous AAT replacement therapy.